Key Factor Supporting Global Theranostics Market Development in 2025: Rising Cancer Prevalence Fuels Growth In The Theranostics Market

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Theranostics Market Size By 2025?
The overall scale of the theranostics sector has experienced swift expansion lately, charting an increase from a valuation of $111.1 billion in 2024 to an anticipated $122.98 billion by 2025, reflecting a compound annual growth rate (CAGR) of 10.7%; this expansion observed during the preceding years is fundamentally linked to progress in molecular imaging techniques, the increasing adoption of value-driven healthcare frameworks, and its incorporation within cancer treatment protocols.

How Big Is the Theranostics Market Size Expected to Grow by 2029?
Projections indicate that the theranostics market is poised for swift expansion over the forthcoming years, reaching a valuation of $184.94 billion by 2029, fueled by a compound annual growth rate (CAGR) of 10.7%. This projected increase throughout the forecast duration stems from several key factors, such as the proliferation of precision medicine efforts, widening utility beyond cancer treatment, demographic shifts toward an older population facing more chronic illnesses, breakthroughs in identifying biomarkers, and augmented backing and financing from governmental bodies. Regarding significant shifts expected in the market during this time frame, these encompass growing regulatory endorsement, the ascent of associated diagnostic tools, a heightened emphasis specifically on theranostics within oncology, greater involvement and understanding among patients, and the melding of different technologies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/theranostics-global-market-report

Which Key Market Drivers Powering Theranostics Market Expansion and Growth?
The escalating incidence of cancer is anticipated to be a primary catalyst for the expansion of the theranostics sector moving ahead. Uncontrolled cellular proliferation characterizes cancer, profoundly affecting numerous bodily systems and accounting for substantial global illness and fatality rates. Theranostics, which merges diagnostic methodologies with therapeutic interventions, demonstrates considerable promise, particularly in addressing cancer and long-term conditions. This methodology facilitates bespoke, focused interventions by consolidating the abilities to identify and treat ailments, thus opening avenues for breakthroughs within the medical field. Consequently, the growing pool of individuals diagnosed with cancer is directly fueling the market for theranostics. As a concrete example illustrating this trend, data released in January 2022 by the National Cancer Institute (NCI)-a US federal entity under the National Institutes of Health (NIH) solely focused on cancer research, prevention efforts, and care-indicated that roughly 5.4 percent of the American populace, translating to 18.1 million persons, have successfully survived cancer. Furthermore, concerning advanced-stage disease, the population living with metastatic forms of breast, prostate, lung, colorectal, or bladder cancer, alongside metastatic melanoma, stood at 623,405 in the year 2022, with projections showing an ascent to 693,452 individuals by 2025, solidifying the assertion that the expanding burden of cancer is the impetus behind theranostics market growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10823&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Theranostics Market?
Leading entities within the theranostics market are prioritizing the creation of sophisticated technological offerings, exemplified by theranostics clinical trials, with the goal of advancing tailored medical care and elevating patient results through the unified application of diagnostic and therapeutic modalities. These clinical research endeavors specifically investigate how combining diagnostic procedures with precisely targeted therapeutic agents can customize treatment plans for unique individuals, assessing treatment efficacy determined by patient-specific biological markers to thereby foster greater personalization in healthcare. A relevant illustration occurred in May 2024 when BAMF Health, a provider of cancer treatments situated in the United States, initiated the COMBAT Trial, formally named "A Phase I/II Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617" (NCT05633160); this trial is distinguished by its swift initiation, achieved in a mere seven weeks thanks to BAMF Health's BAMF RapAct program, and its concentration on employing novel radiopharmaceuticals designed to bind with the Gastrin-Releasing Peptide receptor (GRPR), seeking to broaden therapeutic alternatives for patients facing restricted treatment choices.

What Are the Emerging Segments in the Theranostics Market?
The theranosticsmarket covered in this report is segmented -

1) By Disease Type: Neurological Disorders; Cardiovascular Diseases; Immunological Disorders; Oncology Diseases; Other Diseases
2) By Technology: Polymerase Chain Reaction; Immunohistochemistry; In-Situ Hybridization; Sequencing; Other Technologies
3) By End User: Hospitals And Clinics; Diagnostic Laboratories; Other End Users

Subsegments:
1) By Neurological Disorders: Alzheimer's Disease; Parkinson's Disease; Multiple Sclerosis; Epilepsy; Other Neurological Disorders
2) By Cardiovascular Diseases: Coronary Artery Disease; Heart Failure; Atrial Fibrillation; Hypertension; Other Cardiovascular Diseases
3) By Immunological Disorders: Rheumatoid Arthritis; Systemic Lupus Erythematosus; Inflammatory Bowel Disease; Psoriasis; Other Immunological Disorders
4) By Oncology Diseases: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Other Oncology Diseases
5) By Other Diseases: Infectious Diseases; Metabolic Disorders; Genetic Disorders; Other Diseases

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10823&type=smp

Who Are the Global Leaders in the Theranostics Market?
Major companies operating in the theranostics market include Abbott Laboratories, Agilent Technologies Inc., AmeriPath Inc, Beckman Coulter Inc., Thermo Fisher Scientific Inc, Astellas Pharma, Helmholtz Centre for Infection Research, Radiopharm Theranostics Ltd, Alpha- Theranostics, UNIVERZITET U NOVOM SADU, Cardio-Theranostics LLC, Curium, SoFi Technologies Inc., Theradiag, Cell Theranostics, F. Hoffmann-La Roche AG, GE HealthCare Technologies Inc, Qiagen NV, Foundation Medicine Inc, Leica Biosystems Nussloch GmBH, Pfizer Inc., Siemens Healthineers, Advanced Accelerator Applications, AstraZeneca plc, Bayer AG, Bio-Rad Laboratories, The Bristol-Myers Squibb Company, Danaher Corporation, MilliporeSigma, Illumina Inc., Merck KGaA, Roche Diagnostics Corporation, PerkinElmer Inc.

Which are the Top Profitable Regional Markets for the Theranostics Industry?
North America was the largest region in the global theranostics market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the theranostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10823

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.